Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 3/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 16/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19551492 | 0.91 | KCNJ5 (0.48) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL19552117 | 0.91 | KCNJ5 (0.48) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL22353142 | 0.84 | KCNJ5 (0.49) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL19552082 | 0.84 | P2RX4 (0.55) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL29716936 | 0.84 | P2RX4 (0.55) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL20929134 | 0.81 | KCNJ5 (0.49) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL20929097 | 0.80 | KCNJ5 (0.50) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL22353143 | 0.76 | KCNJ5 (0.44) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL22894354 | 0.75 | KCNJ5 (0.44) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL20916536 | 0.73 | KCNJ6 (0.49) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844016-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-11-24 | — | — | US | disclosed |
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | KCNJ6 2337/4885KCNJ5 1892/4885KCNJ3 2802/4885 |
| US-10844016-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | KCNJ6 2337/4885KCNJ5 1892/4885KCNJ3 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.